0001021561-13-000043.txt : 20130419 0001021561-13-000043.hdr.sgml : 20130419 20130419082540 ACCESSION NUMBER: 0001021561-13-000043 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20130419 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20130419 DATE AS OF CHANGE: 20130419 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NU SKIN ENTERPRISES INC CENTRAL INDEX KEY: 0001021561 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] IRS NUMBER: 870565309 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12421 FILM NUMBER: 13770445 BUSINESS ADDRESS: STREET 1: 75 WEST CENTER ST STREET 2: ATTN: D. MATTHEW DORNY CITY: PROVO STATE: UT ZIP: 84601 BUSINESS PHONE: 801-345-6100 MAIL ADDRESS: STREET 1: 75 WEST CENTER ST STREET 2: ATTN: D. MATTHEW DORNY CITY: PROVO STATE: UT ZIP: 84601 FORMER COMPANY: FORMER CONFORMED NAME: NU SKIN ASIA PACIFIC INC DATE OF NAME CHANGE: 19960919 8-K 1 china8k.htm CHINA FORM 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 
April 19, 2013
 
 
Date of Report (Date of earliest event reported)
 
 
 
 
NU SKIN ENTERPRISES, INC.
 
 
(Exact name of registrant as specified in its charter)
 
 
 
Delaware
 
001-12421
 
87-0565309
(State or other jurisdiction of incorporation)
 
(Commission File Number)
 
 
(IRS Employer Identification Number)
 
75 West Center Street
Provo, UT 84601
 
 
(Address of principal executive offices and zip code)
 
 
 
(801) 345-1000
 
 
(Registrant's telephone number, including area code)
 
 
 
N/A
 
 
(Former name or former address, if changed since last report)
 
 
 

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
□    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
□    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
 

 
 
 
Item 7.01. Regulation FD Disclosure.

On April 19, 2013, Nu Skin Enterprises, Inc. (the "Company") issued a press release to reiterate certain global and Mainland China regional sales goals and provide other updates regarding the Company. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 7.01, is being furnished, not filed, pursuant to Regulation FD. Accordingly, such information will not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference. The furnishing of such information is not intended to, and does not, constitute a determination or admission by the Company as to the materiality of such information.

Item 9.01. Financial Statements and Exhibits.

(d)        Exhibits.
           
99.1      Press release issued by Nu Skin Enterprises, Inc. on April 19, 2013.
 
 
 

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NU SKIN ENTERPRISES, INC.
 (Registrant)


/s/ Ritch Wood
Ritch Wood
 Chief Financial Officer


Date:  April 19, 2013


EXHIBIT INDEX

Exhibit No.                                                                                    Exhibit Description
99.1 Press release issued by Nu Skin Enterprises, Inc. on April 19, 2013

EX-99.1 2 ex99-1.htm PRESS RELEASE DATED APRIL 19, 2013

FOR IMMEDIATE RELEASE

CONTACTS:
Investors — Scott Pond (801) 345-2657, spond@nuskin.com
Media — Kara Schneck (801) 345-2116, kschneck@nuskin.com
 

NU SKIN REITERATES GREATER CHINA REGIONAL SALES GOAL
IN ADVANCE OF MEETINGS WITH SALES LEADERS

Date for first quarter earnings release also announced


PROVO, Utah—April 19, 2013—In connection with its annual incentive trip for Greater China sales leaders,  Nu Skin Enterprises (NYSE:NUS) today reiterated its  goal of reaching $1 billion in annual revenue  in the Greater China region by 2014.

"In 2010, when we set our $1 billion sales goal for the Greater China region, it seemed like an aspirational target," said Truman Hunt, chief executive officer, "However, with  momentum building in the region and the positive response we are receiving from customers in this growing market, we now believe the goal is achievable well within the original time frame.

"Furthermore, we continue to work towards our long-term vision of achieving $5 billion in global annual revenue by 2020. We believe that our global business will continue to perform well into the future as we continue to build on our innovative ageLOC product platform, including our new weight management system scheduled to be introduced later this year."

In addition to the Greater China sales trip, the company will also host its annual Nu Skin Korea convention in Seoul next week. South Korea is one of the company's top markets, and the convention will highlight the ageLOC Body Spa, one of the company's most recent innovations.
 
 
 
-more-
 
 

Nu Skin Enterprises Reiterates Greater China Sales Goal
April 19, 2013
Page 2
 
 
 
The company will release first-quarter results before the opening of the financial market and hold a call with the investment community on May 2, 2013. At that time, the company will provide additional information on the outlook for the second quarter as well as the remainder of 2013. The call will take place at 11 a.m. (EDT). The event will also be webcast on the company's website at www.ir.nuskin.com.

About Nu Skin Enterprises
 
Nu Skin Enterprises, Inc. demonstrates its tradition of innovation through its comprehensive anti-aging product portfolio, independent business opportunity and corporate social responsibility initiatives. The company's scientific leadership in both skin care and nutrition has established Nu Skin as a premier anti-aging company. The company's anti-aging products feature the new ageLOC® suite of products including the ageLOC® R2 nutritional supplement, ageLOC® Galvanic Spa System and ageLOC® Galvanic Body Spa™, as well as the ageLOC® Transformation daily skin care system. A global direct selling company, Nu Skin operates in 53 markets worldwide and is traded on the New York Stock Exchange under the symbol "NUS." More information is available at www.nuskin.com .

Please Note: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended that represent the company's current expectations and beliefs. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws and include, but are not limited to, statements of management's expectations regarding the company's performance, initiatives, goals, strategies and new product introductions; statements of projections regarding global and Mainland China sales targets and goals; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as "believe," "expect," "project," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "could," "may," "might," the negative of these words and other similar words.
The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:
 
 
-more-
 
Nu Skin Enterprises Reiterates Greater China Sales Goal
April 19, 2013
Page 3
·
any changes in operations or future financial results from those currently anticipated;
·
any failure of current or planned initiatives or products to generate interest among distributors and customers and generate sponsoring and selling activities on a sustained basis;
·
risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support our planned initiatives or launch strategies, including possible ingredient supply limitations;
·
risk of foreign currency fluctuations and the currency translation impact on the company's business associated with these fluctuations;
·
regulatory risks associated with the company's products, which could require the company to modify its claims or inhibit the company's ability to import or continue selling a product in a market if it is determined to be a medical device or if it is unable to register the product in a timely manner under applicable regulatory requirements;
·
any inability to secure necessary governmental approvals or licenses to effect any future changes or expansion;
·
continued regulatory scrutiny and investigations in Mainland China, which have from time to time in the past, and could in the future, negatively impact the company's business, including the interruption of sales activities in stores, loss of licenses, and the imposition of fines;
·
adverse publicity related to the company's business, products, industry or any legal actions or complaints by distributors or others; and
·
continued competitive pressures in the company's markets.
The company's financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission.  The forward-looking statements set forth the company's beliefs as of the date that such information was first provided and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.
# # #